Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Deferred Taxes (2019 - 2022)

Pulmonx (LUNG) reported Deferred Taxes of -$49000.0 for Q4 2022, down 388.24% year-over-year from $17000.0 in Q4 2021, and down 388.24% on a QoQ basis from $17000.0 in Q4 2021.

Pulmonx (LUNG) has 4 years of Deferred Taxes data on file, last reported at -$49000.0 in Q4 2022.

  • Quarterly Deferred Taxes fell 388.24% year-over-year to -$49000.0 in Q4 2022, while the trailing twelve-month figure through Mar 2025 was -$49000.0 (changed N/A YoY) and the FY2024 annual result came in at $50000.0, up 308.33% from the prior year.
  • Deferred Taxes eased to -$49000.0 in Q4 2022 per LUNG's latest filing, from $17000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $17000.0 in Q4 2021 and bottomed at -$49000.0 in Q4 2022.
  • The 4-year median for Deferred Taxes is -$10000.0 (2021), against an average of -$10555.6.
  • The widest annual swing landed in 2021, when Deferred Taxes soared 241.67%; it then slumped 388.24% in 2022.
  • Tracing LUNG's Deferred Taxes over 4 years: stood at -$30000.0 in 2019, then soared by 60.0% to -$12000.0 in 2020, then soared by 241.67% to $17000.0 in 2021, then tumbled by 388.24% to -$49000.0 in 2022.
  • Per Business Quant, the three latest LUNG Deferred Taxes figures stand at -$49000.0 (Q4 2022), $17000.0 (Q4 2021), and -$1000.0 (Q2 2021).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -33.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -101.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -351.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -9.40 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 300,000.00
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -16.70 Mn
10 Pulmonx 67.30 Mn -2.45 Mn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 -49,000.00
Dec 31, 2021 17,000.00
Jun 30, 2021 -1,000.00
Mar 31, 2021 -10,000.00
Dec 31, 2020 -12,000.00
Sep 30, 2020 10,000.00
Jun 30, 2020 -1,000.00
Mar 31, 2020 -19,000.00
Dec 31, 2019 -30,000.00